Weight-loss market to see 16 new drugs by 2029, report estimates
Sept 10 (Reuters) -The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, according to estimates from analysts at Morningstar and Pitchbook.
In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031. The 16 drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from these new challengers.
WHY IT'S IMPORTANT
Surging demand for Novo's Wegovy and Lilly's Zepbound has sparked interest among competitors to test their own weight-loss treatments. Companies such as Amgen AMGN.O and Pfizer PFE.N are currently testing their drug candidates in clinical trials.
These developments come amid criticism from lawmakers over the high costs associated with these medications. The new entrants, however, are expected to drive down prices as they vie for market share, according to the report.
CONTEXT
The potential new treatments include those from Boehringer Ingelheim and Zealand Pharma ZELA.CO, along with competitors from Roche ROG.S, Amgen AMGN.O and Pfizer PFE.N, according to the report, provided that the drugs clear clinical trials.
Other entrants include those by Structure Therapeutics GPCR.O, Viking Therapeutics VKTX.O and Altimmune ALT.O, along with next-generation drugs by Novo and Lilly.
Analysts, last year, had forecast the obesity market would be $170 billion by 2031, but have recently raised their estimates, partly due to anticipated higher diabetes market penetration.
The report projects 41% individuals with diabetes and nearly one-quarter of nondiabetic obesity patients will be on a GLP-1 drug by 2031.
WHAT'S NEXT
Analysts expect significant acquisitions by major pharmaceutical companies in the obesity sector over the next 18 months, targeting smaller companies specializing in obesity drug development.
Potential acquisition targets include firms such as Structure, Viking and Altimmune.
Private companies such as NodThera, Corteria and Diasome have a higher-than-50% chance of being acquired, according to PitchBook data.
Reporting by Sneha S K in Bengaluru; Editing by Mohammed Safi Shamsi
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
